Greg Fitzgibbon
Chief Technology Officer & Co-founder @Bubblx
Signup · Get unlimited contacts
WORK HISTORY
Chief Technology Officer & Co-founder @Bubblx
Manchester, GB
Leading technical strategy and execution for a Life-Science/ deep-tech start up at the intersection of nanotechnology and AI-driven respiratory diagnostics. • Built and scaled cross-functional teams across AI/ML, software engineering, and bioinformatics from scratch. • Architected production-ready AI pipelines for biomarker interpretation using agentic models, vector databases, and decision engines. • Spearheaded strategic collaborations with NVIDIA via their Inception program to accelerate AI performance in regulated environments. • Oversaw product development, IP strategy, and security architecture across mobile and cloud platforms. • Navigated early-stage funding and roadmap planning, positioning the company for growth and market entry in Europe.
EDUCATION
Liverpool Blue Coat School
GCSE & A-Levels
The University of Liverpool
BSc(Hons), Genetics
University of York
Master's degree, Computer Science
The University of Liverpool
Doctor of Philosophy (PhD), Molecular Genetics
ABOUT GREG FITZGIBBON
Co-Founder and CTO of BubblX. CEO and founder of Tession Ltd currently consulting on multiple projects including: o Conducting comprehensive scientific due diligence for investors, evaluating the technical and research aspects of companies they are considering for investment, assessing the scientific validity, technological feasibility, and potential risks to ensure informed decision-making. o Scientific Advisory Board Role, providing technical expertise to leaders and innovators. o Clinical and analytical validation, design control, manufacturing and product development pathways to ISO accreditations.o Directed the development of LC-MS and qPCR assay technologies using AI/ML models for early preeclampsia and sepsis detection.o Managed software development for ISO 62304 and ISO 27001 compliance.o Clinical Laboratory Director for Metabolomic Diagnostics (part-time) focused on the development and deployment of AI and machine learning (ML)/deep technologies for improved pregnancy outcomes. CTO for Presymptom Health (part-time) on the development of a product pipeline focused on sepsis diagnostics using AI/ML. Experience and Expertise:o Mergers, Acquisitions & Integration: Extensive experience in conducting due diligence on acquisition targets, including financial, operational, and strategic assessments. Successfully led the acquisition processes for multiple companies, including the acquisition of Elucigene Diagnostics for £10M, The Genome Store and Nell Health to Concepta Diagnostics. Adept at post-acquisition integration, managing seamless transitions of staff, operations, and systems to ensure continued business growth and operational stability.o Former COO of Elucigene Diagnostics, Development, manufacture and launch of over 25 IVDs under ISO 13485, cGMP, MDSAP, IVDD, IVDR. o HCPC registered Clinical Scientist with New York State DOH Certificate of Qualification and a Diplomate of the Royal College of Pathologists (DipRCPath). A Scientific advisory board member for MyHealthChecked. o Previous Clinical Oversight COVID-19 molecular testing service and product development for Yourgene Health and MyHealthChecked. Demonstrated history of working in the biotechnology industry in IVD product and medical lab space. o Skilled in AI/ML, Tech, Biomarkers, Oncology, Molecular Biology, Biotechnology, CLIA, Corporate Governance, M&A and Due Diligence. Strong product management professional with a MSc in Computer Science and PhD in Biological Science/Bioinformatics.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.